These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 3766571)

  • 1. Cost savings achieved through cephalosporin use review and restriction.
    Dzierba SH; Reilly RT; Caselnova DA
    Am J Hosp Pharm; 1986 Sep; 43(9):2194-7. PubMed ID: 3766571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Savings achieved through cephalosporin surveillance.
    Katz E; Schlamowitz S
    Am J Hosp Pharm; 1978 Dec; 35(12):1521-3. PubMed ID: 717407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing physician prescribing habits through a cost-effective first generation cephalosporin formulary.
    Cramer R; Wright C
    Hosp Pharm; 1989 Jan; 24(1):33-8. PubMed ID: 10312858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug usage review and inventory analysis in promoting rational parenteral cephalosporin therapy.
    Simon WA; Thompson L; Campbell S; Lantos RL
    Am J Hosp Pharm; 1975 Nov; 32(11):1116-21. PubMed ID: 1190230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Financial impact of formulary revision of second-generation cephalosporins.
    Andrews JD; Hafting S
    Can J Hosp Pharm; 1988 Jun; 41(3):125-7. PubMed ID: 10288499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions.
    Hayman JN; Sbravati EC
    Am J Hosp Pharm; 1985 Jun; 42(6):1343-7. PubMed ID: 4014250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling financial variables--changing prescribing patterns.
    Abramowitz PW
    Am J Hosp Pharm; 1984 Mar; 41(3):503-15. PubMed ID: 6367444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost containment through restriction of cephalosporins.
    Britton HL; Schwinghammer TL; Romano MJ
    Am J Hosp Pharm; 1981 Dec; 38(12):1897-900. PubMed ID: 7325168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidisciplinary approach to cost reduction of C-section prophylaxis.
    Todd MW; Benrubi G
    Hosp Formul; 1990 Apr; 25(4):446-8, 450. PubMed ID: 10104235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods of controlling cephalosporin use in Canadian hospitals.
    Godin JP; Sketris IS; Merrett RA; Marrie TJ
    Can J Hosp Pharm; 1988 Apr; 41(2):73-4, 83-4, 96. PubMed ID: 10287052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involving physicians in efforts to control pharmaceutical expenditures.
    Shulkin DJ; McGourty ME; Bourret J
    Med Interface; 1995 Aug; 8(8):85-7, 90. PubMed ID: 10144777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of parenteral cephalosporin regulation on pharmacy costs.
    Ryan JL; Francese J
    Hosp Formul; 1983 May; 18(5):510-2. PubMed ID: 10260198
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical pharmacist impact on parenteral cephalosporin prescribing.
    Lawlor MC; Lucarotti RL
    Hosp Formul; 1983 Apr; 18(4):402-4, 407-8. PubMed ID: 10259512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An approach to regulating cephalosporin use and costs.
    Ryan JL; Francese J
    Hosp Formul; 1980 Sep; 15(9):674-6. PubMed ID: 10248357
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacy U.R. cuts costs, drug use.
    Mosier RL
    Hosp Peer Rev; 1979 May; 4(5):70-2. PubMed ID: 10308905
    [No Abstract]   [Full Text] [Related]  

  • 16. Contribution of clinical pharmacists to cefazolin utilization.
    Witte KW; Hatoum HT; Hoon TJ
    Hosp Formul; 1987 Aug; 22(8):737-41. PubMed ID: 10283405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computer-assisted antimicrobial-use monitoring.
    Inaraja MT; Paloma JM; Giráldez J; Idoate AJ; Hualde S
    Am J Hosp Pharm; 1986 Mar; 43(3):664-70. PubMed ID: 3754692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cephalosporin-use restrictions in teaching hospitals.
    McCloskey WW; Johnson PN; Jeffrey LP
    Am J Hosp Pharm; 1984 Nov; 41(11):2359-62. PubMed ID: 6507437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of clinical pharmacists to reduce cefamandole, cefoxitin, and ticarcillin costs.
    Abramowitz PW; Nold EG; Hatfield SM
    Am J Hosp Pharm; 1982 Jul; 39(7):1176-80. PubMed ID: 7114059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategy for developing a safe and cost-effective H2-receptor antagonist program.
    Quercia RA; Chow MS; Jay GT; Quintiliani R
    Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.